BP41072 - AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/ REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA.

  • Inam, Shafqat (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date20/11/24 → 19/11/26

Keywords

  • Clinical Trials
  • BP41072